David Cameron

Corewell Health

Biochemistry, Genetics and Molecular Biology · Life Sciences

108h-index65.7kcitations1.0kworks5.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Breast Cancer Treatment Studies(294), HER2/EGFR in Cancer Research(261), Cancer Treatment and Pharmacology(216), Advanced Breast Cancer Therapies(213), Cancer Genomics and Diagnostics(77)

Publications1.0k total

A marble in the heart: CMR for the diagnosis of a rare intracardiac mass
Journal of Cardiovascular Magnetic Resonance·2026Open Access
Molecular and Clinical Analyses of Gene Fusions Identify Therapeutic Targets in Paired Primary and Metastatic Breast Cancer from the AURORA Program (BIG 14-01)
Clinical Cancer Research·2025
Table 1 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
2025Open Access
Table 2 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
2025Open Access
Figure 3 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
2025Open Access
Figure 1 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
2025Open Access
Figure 2 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
2025Open Access
Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02
Annals of Oncology·2025Open Access
The Breast International Group (BIG) Patient Partnership: Embedding meaningful patient involvement in the design and conduct of breast cancer clinical research
The Breast·2025Open Access
Ten-Year Survival after Postmastectomy Chest-Wall Irradiation in Breast Cancer
New England Journal of Medicine·2025· 8 citedOpen Access
Tailoring treatment to cancer risk and patient preference: the 2025 St Gallen International Breast Cancer Consensus Statement on individualizing therapy for patients with early breast cancer
Annals of Oncology·2025· 5 citedOpen Access
Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial
Nature Medicine·2025· 7 citedOpen Access
Quality Improvement Intervention, the Addition of Lifestyle Medicine Group Sessions in Multiple Myeloma Population
Clinical Lymphoma Myeloma & Leukemia·2025
Association Between Daily Timing of Everolimus and Survival in High‐Risk <scp>HR</scp> +/ <scp>HER2</scp> − Early Breast Cancer: A Sub‐Analysis of the UCBG‐UNIRAD Trial
Clinical Pharmacology & Therapeutics·2025Open Access
Hidden costs and unmet supportive care needs among individuals with experience of breast cancer and their carers in the United Kingdom
BJC Reports·2025Open Access
Predicting ovarian function loss after chemotherapy and anti-HER2 therapy in young breast cancer patients
JNCI Journal of the National Cancer Institute·2025· 4 citedOpen Access
Phaeochromocytomas and paragangliomas harbour tumour-initiating SOX2+ stem cells
2025Open Access
Abstract P2-01-08: Follow-up in Early and Locally Advanced Breast Cancer Patients: An EORTC QLG-BCG- ROG study
Clinical Cancer Research·2025
Abstract P2-08-21: ELEGANT: Elacestrant versus standard endocrine therapy in women &amp; men with node-positive, estrogen receptor-positive, HER2-negative, early breast cancer with high risk of recurrence in a global, multicenter, randomized, open-label phase 3 study
Clinical Cancer Research·2025
Abstract RF3-07: ROSCO: Response to Optimal Selection of neoadjuvant Chemotherapy in Operable breast cancer: Randomised phase III, stratified biomarker trial of neoadjuvant 5-Fluorouracil,Epirubicin &amp; Cyclophosphamide vs Docetaxel &amp; Cyclophosphamide chemotherapy
Clinical Cancer Research·2025
page 1 of 52Next →

Frequent Co-authors

Martine Piccart(14), Jonas Bergh(11), Sibylle Loibl(9), Eric P. Winer(9), Richard H. Bell(8), Richard D. Gelber(8), Michael Untch(7), Luca Gianni(7), Mitch Dowsett(7), Andrew Wardley(7), Michael Gnant(7), Giuseppe Viale(7), Aron Goldhirsch(6), José Baselga(6), Charles E. Geyer(6), Mario Campone(6), Nadia Harbeck(6), Karen A. Gelmon(6), Judith M. Bliss(6), David Dodwell(6)